跳转至内容
Merck
所有图片(1)

文件

HKI4MAG-99K

Millipore

MILLIPLEX® Human Kidney Injury Magnetic Bead Panel 4 - Toxicity Multiplex Assay

The analytes available for this multiplex kit are: EGF, FABP1, IP-10, KIM-1, Osteopontin (OPN), PTH and Renin.

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12161503
eCl@ss:
32161000
NACRES:
NA.84

品質等級

物種活性

human

製造商/商標名

Milliplex®

assay range

accuracy: 63-118%
intra-assay cv: <10
sensitivity: 0.01-0.71 ng/mL
(MinDC+2SD)

standard curve range: 0.01-5 ng/mL
(IP-10)

standard curve range: 0.012-12.5 ng/mL
(EGF)

standard curve range: 0.02-20 ng/mL
(PTH)

standard curve range: 0.15-150 ng/mL
(FABP1)

standard curve range: 0.17-1,200 ng/mL
(Osteopontin (OPN))

standard curve range: 0.20-200 ng/mL
(KIM-1)

standard curve range: 0.68-700 ng/mL
(Renin)

技術

multiplexing: suitable

檢測方法

fluorometric (Luminex xMAP)

運輸包裝

wet ice

一般說明

Maintenance of physiological balance in the body is attributed in part to normal kidney function. Altered kidney function due to injury, drug toxicity or kidney failure may be life threatening. Toxicity is the leading cause of drug failure, so research is expanding in search of more sensitive, rapid methods to determine organ-specific damage as quickly as possible. Traditionally, blood urea nitrogen (BUN) and serum creatinine tests have been used to determine drug-induced damage to the kidney. These tests only detect kidney damage after it begins and do not allow for the elucidation of where in the kidney the damage has occurred. Specificity and earlier detection of kidney injury is vital, and this area of research is expanding in search of more sensitive, rapid methods for determining the specific area of damage in kidney.

The MILLIPLEX® portfolio provides valuable research assays to investigate multiple biomarkers of kidney injury in human serum and plasma samples using the Luminex® xMAP® instrument platform.

The MILLIPLEX® Human Kidney Injury Bead Panel 4 contains all the components necessary to measure the following seven biomarkers in any combination using Luminex® xMAP® technology: EGF, FABP1, IP-10, KIM-1, Osteopontin (OPN), PTH and Renin. The kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 serum or plasma samples in duplicate.

Panel Type: Toxicity

特異性

Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.

應用

  • Analytes: EGF, FABP1, IP-10, KIM-1, Osteopontin (OPN), PTH, Renin
  • Recommended Sample type: serum and plasma
  • Recommended Sample dilution: 1:2 in kit Assay Buffer. Customers need to determine the optimal dilution factor for their samples. Our recommendations are on serum and plasma samples from normal subjects.
  • Assay Run Time: Overnight
  • Research Category: Toxicity

特點和優勢

Design your multiplex kit by choosing available analytes within this panel.

包裝

Everything you need in a single kit.

儲存和穩定性

Recommended storage for kit components is 2 - 8°C.

其他說明

Please contact Technical Service for linearity of dilution.
Sensitivity: Please see kit protocol for individual assay sensitivities.

法律資訊

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

標靶器官

Respiratory Tract

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Annie Moisan et al.
Molecular therapy. Nucleic acids, 6, 89-105 (2017-03-23)
Antisense oligonucleotide (AON) therapeutics offer new avenues to pursue clinically relevant targets inaccessible with other technologies. Advances in improving AON affinity and stability by incorporation of high affinity nucleotides, such as locked nucleic acids (LNA), have sometimes been stifled by

相关内容

Multiplex kidney toxicity assays detect nephrotoxicity biomarkers in small samples, minimizing time and costs for toxicity screening.

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门